ArticleEuropean radiology experimental2026
¹⁹F MRI radiomic features: in vitro and in vivo repeatability.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multinuclear NMR and MRI Beyond Proton Imaging: Principles, Contrast Mechanisms, and Applications in Materials and Biomedicine.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUsing radiomics to compute quantitative imaging features may reveal information beyond standard magnetic resonance imaging (MRI) metrics. We aim to investigate the test-retest repeatability of ¹⁹F MRI radiomic features in phantoms containing two perfluorocarbons and to validate these findings in a pilot in vivo mouse tumor model. MATERIALS AND
methodsTwo phantoms containing perfluoropolyether (PFPE) or perfluoro-15-crown-5 ether (PFCE) were repeatedly scanned (intrasession and intersession) using a 7-T system equipped with a dual-tuned ¹H/¹⁹F volume coil. Radiomic features were extracted and assessed for stability using the concordance correlation coefficient (CCC) ≥ 0.85 and normalized dynamic range ≥ 0.90. A separate in vivo test-retest experiment was conducted in tumor-bearing mice injected with a PFPE nanoemulsion.
resultsA total of 194 scans and 772 segments were evaluated across the PFPE phantom, PFCE phantom, and in vivo experiments. In both phantoms, radiomic features displayed high intrasession repeatability (median CCC up to 0.886) but decreased intersession repeatability (median CCC down to 0.683). Intensity features were consistently more repeatable (p < 0.003) than shape or texture features. We found that 23.1% (466/2,013) of features were repeatable across phantoms. In vivo pilot scans showed that 86.1% (401/466) of these phantom-stable features, or ~20.0% overall, remained repeatable under physiological conditions.
conclusionSeveral ¹⁹F MRI-derived features exhibited excellent short-term repeatability, and a considerable proportion proved robust to intersession variability. These robust features may reliably capture ¹⁹F signals under both phantom and physiological conditions, paving the way for more quantitative imaging analysis in this modality and encouraging general reproducibility of data. RELEVANCE STATEMENT: KEY POINTS: We analyzed 194 ¹⁹F MRI scans and 772 segments obtained in phantoms at 7 T. Cross-agent stability identified 466 radiomic features meeting concordance correlation coefficient ≥ 0.85 and normalized dynamic range ≥ 0.90. Of these phantom-stable features, 401 of 466 remained stable in vivo in a tumor mouse model. Intensity features were most repeatable, while shape features were least stable across sessions. Median concordance correlation coefficient dropped from 0.886 intrasession to 0.683 intersession.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.